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Figure 1.
The structure of cationic derivatives of cholesterol with
an amino head group: OH-Chol; cholesteryl-3ß-carboxya
midoethylene-N-hydroxyethylamine, DC-Chol; 3([N-(N’,N
’-dimethylaminoethane)-carbamoyl] cholesterol, HAPC-
Chol; N-hydroxyethyl aminopropane carbamoyl choles-
terol, MHAPC-Chol; N,N-methyl hydroxyethyl
aminopropane carbamoyl cholesterol, DMAPC-Chol; N,N
,N-dimethyl aminopropane carbamoyl cholesterol.
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Values represent the means?S.D. (n=3). a) Nanoplex formed in water. 
Figure 2.
Effect of cationic lipid on transfection in human pros-
tate tumor PC-3 cells (A). Each nanoplex was prepared
by mixing plasmid pCMV-luc encoding luciferase gene
under the control of cytomegalovirus (CMV) promoter
with nanoparticle at a charge ratio (+/-) of 3/1. Effect of
charge ratio (+/-) in forming nanoplex on transfection
into PC-3 cells (B). NP-OH nanoplexes were prepared
by mixing pCMV-luc with NP-OH nanoparticles at vari-
ous ratios (+/-); Lipofectamine 2000, DMRIE-C,
Transfectin and Tfx20 according to the manufacturer’s
instructions. In A and B, the luciferase assay was car-
ried out 24 h after incubation of the nanoplexes.
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Figure 3.
Tumor transfection in vivo. Xenografts of PC-3 tumor
cells were directly injected with NP-OH nanoplex
formed at a charge ratio (+/-) of 1/1 or 3/1; in vivo
jetPEI according to the manufacturer’s instructions; and
naked plasmid DNA. Twenty-four hours after i.t. injec-
tions, mice were imaged and bioluminescence was quan-
tified. In A, pseudocolor images representing light emit-
ted from tumors superimposed over grayscale reference
images of representative mice from each group of three.
In B, Quantification of emitted photons from each
tumor. Each column represents the mean ? S.D. (n=3).
Statistical significance was evaluated by Student’s t
test. *P<0.05.
Figure 4.
Suppression of gene expression by siRNA (A) or shRNA
pDNA (B) transfection with nanoparticles in luciferase
stably expressing PC-3 cells. In A, each nanoplex of
luciferase or control siRNA was prepared at a charge
ratio (+/-) of 3/1. In B, nanoplexes of luciferase or con-
trol shRNA pDNA were prepared at a charge ratio (+/-)
of 3/1. In A and B, the luciferase assay was carried out
48 h after incubation of the nanoplexes. The values are
expressed as the mean?S.D. (n=3). Statistical signifi-
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Figure 5.
Effect of charge ratios (+/-) in forming nanoplex of
siRNA on in vitro (A) and in vivo transfections (B). In
A, NP-OH nanoplexes were prepared by mixing siRNA
with NP-OH nanoparticles at various ratios (+/-) and
transfected into luciferase stably expressing PC-3 cells.
The luciferase assay was carried out 48 h after incuba-
tion of the nanoplexes. In B, human colon tumor HT-29
tumor xenografts which stably expressed luciferase were
directly injected with nanoplex of 10? g siRNA.
Seventy-two hours after i.t. injections, mice were im-
aged by an NightOWL LB981 NC100 system and biolu-
minescence was quantified. Each column represents the
mean ? S.D. (n=3). N.D., not done. Statistical signifi-
cance was evaluated by Student’s t test. *P<0.05, **P
<0.01.
Figure 6.
Schematic structure of the folate-linked nanoparticles
composed of folate-PEG2000-DSPE, OH-Chol and Tween
80 (NP-F) (A). Association of FITC-labeled nanoplex
with human nasopharyngeal tumor KB cells 3 h after
transfection in the absence or presence of free folic acid
(B, C). The association was determined based on FITC-
fluorescence by flow cytometry. Flow cytometry of cells
exposed to the nanoplex (continuous line). Dotted line,
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Figure 7.
In vivo suicide gene therapy for KB tumor xenografts
with GCV in mice. Mice were divided into two groups:
group I, control pDNA (10?g); group II, pCMV-tk (10
?g). The NP-F nanoplexes of the pDNAs were injected
directly into the tumor four times (day 0, 2, 4, and 6).
GCV (25 mg/kg) was administered i.p. at 24 and 36 h
after the injections. Tumor volume (A) was measured
over time. On day 14, all mice were killed, and tumor
weight (B) was measured. The results in A and B indi-
cate the mean volume and weight ? S.E. or S.D., re-
spectively (n=5). *P<0.05 and **P<0.01, compared with
control.
Figure 8.
In vivo combination therapy of PC-3 tumor xenografts
with Cx43 pDNA and docetaxel in mice. When the aver-
age volume of PC-3 xenograft tumors reached 200 mm3
(day 0), these mice were selected for treatment with
docetaxel (DTX) alone, control pDNA, connexin 43
(Cx43) pDNA, control pDNA plus DTX and Cx43 pDNA
plus DTX. Nanoplexes of 10?g pDNA per tumor were
directly injected into xenografts on days 0 and 1. DTX
at a dose of 15 mg/kg was injected i.v. on days 0.
Tumor volume (A) was measured on days 0, 3, 6, 9, 11,
13, 15. On day 15, all mice were killed, and macro-
scopic tumor appearance (B) was evaluated. Data are
shown as the mean ? S.E. (A). n=4 for each group. *,
p < 0.05.
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In vivo combination therapy of HER-2 siRNA and paclitaxel for KB tumor xenografts (A). When the average volume
of KB tumor xenografts reached at 100 mm3 (day 0), HER-2 or Control siRNA were directly injected into tumor on
days 0, 3, 6 and 9. Paclitaxel (PTX) at a dose of 5 mg/kg was injected i.v. on days 1, 4, 7 and 10. In vivo combination
therapy of HER-2 shRNA pDNA and PTX for KB tumor xenografts (B). HER-2 or Control shRNA pDNA were directly
injected into tumor on days 0, 3, 6 and 9. PTX at a dose of 5 mg/kg was injected i.v. on days 1, 4, 7 and 10. In A
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Cationic Cholesterol Derivative-Based Nanoparticles for Cancer Gene Therapy
Yoshiyuki HATTORI
Institute of Medicinal Chemistry, Hoshi University
Cancer gene therapy has been intensively developed using non-viral vectors, among which cationic liposomes and
nanoparticles are the most investigated. Optimal gene therapy for tumors must deliver plasmid DNA (pDNA) or syn-
thetic small interfering RNA (siRNA) to tumor cells with high efficiency and minimal toxicity. We developed new
cationic nanoparticles (NP) composed of cholesteryl-3ß-carboxyamidoethylene-N-hydroxyethylamine (OH-Chol) and
Tween 80, and evaluated the transfection efficiencies of pDNA and siRNA into human prostate tumor PC-3
xenografts. NP showed effective transfection of pDNA and siRNA when directly injected into the xenografts. For tar-
geted delivery to tumors, vitamin folic acid has been utilized for folate receptor (FR)-mediated drug delivery since FR
is frequently overexpressed on many types of human tumors. We developed folate-linked nanoparticles (NP-F) com-
posed of OH-Chol, Tween 80 and folate-poly(ethylene glycol)-distearoylphosphatidylethanolamine conjugate. Tumor
growth of FR-positive human nasopharyngeal tumor KB xenografts was significantly inhibited when a complex of
NP-F and a therapeutic gene was intratumorally injected. These findings suggested that cationic cholesterol-based
nanoparticles were potential non-viral pDNA and siRNA vectors for local tumor treatment.
